Call for Abstract

International Conference on Frontiers in Lung Cancer , will be organized around the theme “Prodigious Discoveries in Lung Cancer”

LUNG CANCER 2020 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in LUNG CANCER 2020

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Carcinoid tumors
  • Track 1-2Mucoepidermoid carcinoma
  • Track 1-3Causes of cancer
  • Track 1-4Adenoid cystic carcinoma

Only a fraction of cigarette smokers develops lung cancer, suggesting that people differ in their susceptibility to this disease. We investigated whether differences in DNA Repair Capacity (DRC) for repairing tobacco carcinogen-induced DNA damage are associated with differential susceptibility to lung cancer.

  • Track 2-1Cell Lung Cancer Adhesion Molecules
  • Track 2-2Genetic Mutations
  • Track 2-3Gene Silencing
  • Track 2-4Chromosomal Changes
  • Track 2-5Genomic Instability

Small cell lung cancer (SCLC) makes up less than 20% of lung cancers and is typically caused by tobacco smoking. It often starts in the bronchi, then quickly grows and spreads to other parts of the body, including the lymph nodes.

Non-small cell lung cancer (NSCLC) makes up about 85% of diagnosed lung cancers. These includes all kinds of epithelial lung cancer excluding the small cell lung carcinoma types and are generally more insensitive to chemotherapy.

 

  • Track 3-1Adenocarcinoma
  • Track 3-2Squamous Cell Carcinoma
  • Track 3-3Large Cell Carcinoma
  • Track 3-4Adenosquamous Carcinoma
  • Track 3-5Carcomatoid Carcinoma
  • Track 3-6Lung Carcinoid Tumors
  • Track 3-7Adenoid Cystic Carcinoma
  • Track 3-8Small Cell Lung Cancer Staging
  • Track 3-9Non-Small Cell Lung Cancer Staging

 Risk factors increase an individual’s chance of developing cancer. Risk factors for lung cancer includ

Tobacco smoking

Contact with radon,

asbestos or other cancer-causing agents

Personal history of smoking related cancer

Family history of lung cancer

Lung cancer symptoms may include chronic cough, breathing changes, chest ache, wheezing, hoarse voice, tiredness, weight loss, headache and even bone pain. In certain chronic lung diseases, people with lung cancer don't have symptoms until the cancer is advanced.

 

  • Track 4-1Smoking of Tobacco
  • Track 4-2Family History of Lung Cancer
  • Track 4-3Occupational Hazards
  • Track 4-4Bronchorrhea
  • Track 4-5Coughing up Blood
  • Track 4-6Weight Loss with Unknown Cause

 Lung disease ranges from bronchitis and pneumonia to pulmonary hypertension. Lung function tests and X-rays are used to diagnosis the problem. Many symptoms can be eased with proper treatment. If not treated they may directly or indirectly lead to lung cancer.

 

  • Track 5-1Tuberculosis
  • Track 5-2COPD
  • Track 5-3Asthma
  • Track 5-4Bronchitis
  • Track 5-5Pneumonia
  • Track 5-6Cystic Fibrosis
  • Track 5-7Pulmonary Hypertension
  • Track 5-8Tuberous Sclerosis Complex (TSC)
  • Track 5-9Reactive Airway Disease
  • Track 5-10Allergies

Alpha-1 antitrypsin lack (Alpha1-antitrypsin insufficiency, A1AD, or AATD) is a hereditary issue that causes faulty creation of alpha-1 antitrypsin (A1AT), prompting diminished A1AT movement in the blood and lungs, and affidavit of intemperate irregular A1AT protein in liver cells leading to lung illness and liver infection. Influenced people frequently develop emphysema, which is a lung infection caused by damage to alveoli. Alpha-1 antitrypsin deficiency (A1AD or AATD) is a genetic disorder that may result in lung disease or liver disease. Onset of lung problems is typically between 20 and 50 years old. This may result in shortness of breath, wheezing, or an increased risk of lung infections.

  • Track 6-1Pneumothorax
  • Track 6-2Bronchiectasis
  • Track 6-3Emphysema
  • Track 6-4Granulomatosis with polyangiitis

Genetic mutations that are known to play critical roles in the development and progression of NSCLC include:

 

 

 

 

  •  Epidermal growth factor receptor (EGFR) – the EGFR gene is responsible for a protein that helps a cell respond to its environment and can trigger cell growth, division, and survival.
  •  KRAS – the KRAS gene is involved in regulating cell division.
  •  Anaplastic lymphoma kinase (ALK) – the ALK gene provides instructions for a protein that plays an important role in cell growth, division, and maturation.
  • \r\n

 

  • Track 7-1Epidermal Growth Factor Receptor (EGFR)
  • Track 7-2Kirsten RAS (KRAS)
  • Track 7-3Anaplastic Lymphoma Kinase (ALK)
  • Track 7-4Other Genetic Abnormalities in NSCLC

ARDS, or acute respiratory distress syndrome, is a lung condition that leads to low oxygen levels in the blood. ARDS can be life threatening because organs, such as the kidneys and brain, need oxygen-rich blood to work properly. Most people who develop ARDS are in the hospital for other serious health problems. Rarely, people who aren't hospitalized have health problems that lead to ARDS, such as severe pneumonia. Causes of ARDS includes infections, injuries, or other conditions that cause the lung's tiny blood vessels to leak more fluid than normal into the lungs' air sacs. This prevents the lungs from filling with air and moving enough oxygen into the bloodstream.

 

  • Track 8-1What is ARDS
  • Track 8-2Symptoms and Signs of ARDS
  • Track 8-3Causes of ARDS
  • Track 8-4Treatment of ARDS
  • Track 9-1Pleuropulmonary Blastoma (PPB)
  • Track 9-2Types of PPB
  • Track 9-3Diagnosis of PPB
  • Track 9-4Treatment of PPB

 The implementation of molecular biomarkers in routine practice continues to be challenging. First, physicians must know which biomarkers should be analyzed in routine practice and be aware that additional markers may soon become standard. In this context, regularly updated guidelines can support physicians in their decisions. Nevertheless, clinical implementation of molecular biomarkers may differ among regions based on prevalence of the biomarker, availability of test methods, and access to corresponding treatments.

 

  • Track 10-1Aptahistochemistry for Identification of Lung Cancer Biomarkers
  • Track 10-2Biomarkers of Different Histological Lung Cancer Types
  • Track 10-3Biomarkers of Lung Cancer
  • Track 10-4Conventional Protein Biomarkers of Lung Cancer
  • Track 11-1Low Dose Computer Tomography (LDCT)
  • Track 11-2Screening Profile
  • Track 11-3Lactic Acid Dehydrogenase (LDH) Test
  • Track 11-4Lung Cancer Diagnosis Using Aptamers
  • Track 12-1X-ray of Chest
  • Track 12-2CT Scan of Chest and Upper Abdomen
  • Track 12-3Bronchoscopy
  • Track 12-4Thoracoscopy
  • Track 12-5Mediastinoscopy
  • Track 12-6FNA for Peripheral Tumors
  • Track 12-7Bone scan and Cranial CT Scan
  • Track 13-1Smoking Cessation
  • Track 13-2Avoiding Secondhand Smoke
  • Track 13-3Protection of Lungs at Work and Outdoors
  • Track 13-4Testing Home for Radon
  • Track 13-5Early Detection through Regular Screening
  • Track 14-1Video-assisted thoracic surgery (VATS)
  • Track 14-2Robotic-assisted thoracic surgery
  • Track 14-3Lobectomy
  • Track 14-4Sublobar Resection
  • Track 14-5Segmentectomy
  • Track 14-6Pneumonectomy
  • Track 14-7Wedge resection
  • Track 14-8Bronchoplastic Resection
  • Track 15-1Radical Radiotherapy
  • Track 15-2Continuous High Fractionated Accelerated Radiotherapy (CHART)
  • Track 15-3Brachytherapy
  • Track 15-4Prophylactic Cranial Irradiation (PCI)
  • Track 15-5Palliative Radiotherapy
  • Track 16-1Adjuvant Chemotherapy
  • Track 16-2Pre-surgery Chemotherapy
  • Track 16-3Adverse Drug Reaction
  • Track 16-4Palliative care in Chemotherapy
  • Track 17-1Anti-angiogenesis therapy
  • Track 17-2Epidermal growth factor receptor (EGFR) inhibitors
  • Track 17-3Drugs targeting ALK gene mutations
  • Track 17-4Drugs targeting other genetic changes
  • Track 18-1Advances in Molecular Therapy
  • Track 18-2Immune Checkpoint Inhibition in Lung Cancer
  • Track 18-3CIMA vax